BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

...two days after Hillhouse invested HK$1.3 billion in new shares of CNS and cancer play Luye Pharma Group...
BioCentury | Jan 23, 2020
Politics & Policy

MNCs lead price cuts in China’s second round of centralized procurement

...Precose acarbose. Bayer took a nearly 90% price cut for Precose, sharing the win with Luye Pharma Group...
BioCentury | Dec 4, 2019
Company News

Dec. 3 Company Quick Takes: Brii adds neuroscience focus; plus Immunomedics, Hanmi-Rapt, Luye-Boan and Cara

...an additional $108 million in milestones, plus double-digit royalties. Luye takes out biologics company Boan Luye Pharma Group...
...TACSTD2; EGP-1) - Tumor-associated calcium signal transducer 2 BioCentury Staff Brii Biosciences Immunomedics Inc. Hanmi Pharmaceutical Co. Ltd. RAPT Therapeutics Inc. Luye Pharma Group...
BioCentury | May 1, 2019
Company News

April 30 Company Quick Takes: Merck, G1, Pfizer, Amgen and more

...new medicines, medical devices and biomarkers. Luye to develop PharmaMar's RNA polymerase inhibitor in China Luye Pharma Group...
...655066) trilaciclib (G1T28, iv g1t28-1) Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) AbbVie Inc. Amgen Inc. Bayer AG EirGenix Inc. G1 Therapeutics Inc. Johnson & Johnson Luye Pharma Group...
BioCentury | Mar 29, 2019
Company News

Luye submits NDA for schizophrenia, bipolar disorder therapy

...NDA to FDA for Rykindo risperidone extended-release microspheres (LY03004) to treat schizophrenia and bipolar disorder. Luye Pharma Group...
...of oral antipsychotic therapy when beginning treatment. Hongjiang Li, Staff Writer LY03004 Risperdal Consta, risperidone (Risperdal depot) Johnson & Johnson Luye Pharma Group...
BioCentury | Feb 7, 2019
Finance

Chinese Innovation: Threat or Opportunity?

...firms, such as Jiangsu Hengrui Medicine Co. Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd. and Luye Pharma Group...
...found here . Companies and Institutions Mentioned Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276), Lianyungang, China Luye Pharma Group...
...Pharmaceutical Group Co. Ltd. (Shanghai: 600196; HKEX:2196), Shanghai, China George Baeder, dMed Biopharmaceutical Jiangsu Hengrui Medicine Co. Ltd. Luye Pharma Group...
BioCentury | Feb 7, 2019
Finance

中国创新:威胁还是机遇?

...Baeder是缔脉生物医药科技有限公司的战略和业务发展高级副总裁。 George Baeder,缔脉生物医药科技有限公司 Jiangsu Hengrui Medicine Co. Ltd. Luye Pharma Group...
BioCentury | Jan 18, 2019
Company News

AZ to promote Luye's locally developed CV drug in China

...China's Luye Pharma Group Ltd. (HKEX:2186) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) exclusive rights to promote Luye's blood lipid...
...16. Luye Pharma Group Ltd. (HKEX:2186), Shanghai, China AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Cardiovascular Hongjiang Li AstraZeneca plc Luye Pharma Group...
BioCentury | Jan 16, 2019
Company News

AZ to promote Luye's locally developed CV drug in China

...China's Luye Pharma Group Ltd. (HKEX:2186) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) exclusive rights to promote Luye's blood lipid...
...List (NRDL) and essential drug list. Luye’s stock gained HK$0.31 to HK$5.54 on Wednesday. Hongjiang Li AstraZeneca plc Luye Pharma Group...
BioCentury | Sep 12, 2018
Politics & Policy

China biopharma stocks fall after centralized tendering talks

...Group Ltd. (HKEX:1093) dropped HK$1.80 (10%) to HK$16.70; 3SBio Inc. (HKEX:1530) shed HK$1.02 to HK$13.30; Luye Pharma Group...
Items per page:
1 - 10 of 58
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

...two days after Hillhouse invested HK$1.3 billion in new shares of CNS and cancer play Luye Pharma Group...
BioCentury | Jan 23, 2020
Politics & Policy

MNCs lead price cuts in China’s second round of centralized procurement

...Precose acarbose. Bayer took a nearly 90% price cut for Precose, sharing the win with Luye Pharma Group...
BioCentury | Dec 4, 2019
Company News

Dec. 3 Company Quick Takes: Brii adds neuroscience focus; plus Immunomedics, Hanmi-Rapt, Luye-Boan and Cara

...an additional $108 million in milestones, plus double-digit royalties. Luye takes out biologics company Boan Luye Pharma Group...
...TACSTD2; EGP-1) - Tumor-associated calcium signal transducer 2 BioCentury Staff Brii Biosciences Immunomedics Inc. Hanmi Pharmaceutical Co. Ltd. RAPT Therapeutics Inc. Luye Pharma Group...
BioCentury | May 1, 2019
Company News

April 30 Company Quick Takes: Merck, G1, Pfizer, Amgen and more

...new medicines, medical devices and biomarkers. Luye to develop PharmaMar's RNA polymerase inhibitor in China Luye Pharma Group...
...655066) trilaciclib (G1T28, iv g1t28-1) Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) AbbVie Inc. Amgen Inc. Bayer AG EirGenix Inc. G1 Therapeutics Inc. Johnson & Johnson Luye Pharma Group...
BioCentury | Mar 29, 2019
Company News

Luye submits NDA for schizophrenia, bipolar disorder therapy

...NDA to FDA for Rykindo risperidone extended-release microspheres (LY03004) to treat schizophrenia and bipolar disorder. Luye Pharma Group...
...of oral antipsychotic therapy when beginning treatment. Hongjiang Li, Staff Writer LY03004 Risperdal Consta, risperidone (Risperdal depot) Johnson & Johnson Luye Pharma Group...
BioCentury | Feb 7, 2019
Finance

Chinese Innovation: Threat or Opportunity?

...firms, such as Jiangsu Hengrui Medicine Co. Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd. and Luye Pharma Group...
...found here . Companies and Institutions Mentioned Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276), Lianyungang, China Luye Pharma Group...
...Pharmaceutical Group Co. Ltd. (Shanghai: 600196; HKEX:2196), Shanghai, China George Baeder, dMed Biopharmaceutical Jiangsu Hengrui Medicine Co. Ltd. Luye Pharma Group...
BioCentury | Feb 7, 2019
Finance

中国创新:威胁还是机遇?

...Baeder是缔脉生物医药科技有限公司的战略和业务发展高级副总裁。 George Baeder,缔脉生物医药科技有限公司 Jiangsu Hengrui Medicine Co. Ltd. Luye Pharma Group...
BioCentury | Jan 18, 2019
Company News

AZ to promote Luye's locally developed CV drug in China

...China's Luye Pharma Group Ltd. (HKEX:2186) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) exclusive rights to promote Luye's blood lipid...
...16. Luye Pharma Group Ltd. (HKEX:2186), Shanghai, China AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Cardiovascular Hongjiang Li AstraZeneca plc Luye Pharma Group...
BioCentury | Jan 16, 2019
Company News

AZ to promote Luye's locally developed CV drug in China

...China's Luye Pharma Group Ltd. (HKEX:2186) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) exclusive rights to promote Luye's blood lipid...
...List (NRDL) and essential drug list. Luye’s stock gained HK$0.31 to HK$5.54 on Wednesday. Hongjiang Li AstraZeneca plc Luye Pharma Group...
BioCentury | Sep 12, 2018
Politics & Policy

China biopharma stocks fall after centralized tendering talks

...Group Ltd. (HKEX:1093) dropped HK$1.80 (10%) to HK$16.70; 3SBio Inc. (HKEX:1530) shed HK$1.02 to HK$13.30; Luye Pharma Group...
Items per page:
1 - 10 of 58